Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Dec;40(6):523–530. doi: 10.1111/j.1365-2125.1995.tb05796.x

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

K T Kivistö 1, H K Kroemer 1, M Eichelbaum 1
PMCID: PMC1365206  PMID: 8703657

Abstract

1. Little information is available about the pharmacokinetic interactions of anticancer drugs in man. However, clinically significant drug interactions do occur in cancer chemotherapy, and it is likely that important interactions have not been recognized. 2. Specific cytochrome P450 (CYP) enzymes have been recently shown to be involved in the metabolism of several essential anticancer agents. In particular, enzymes of the CYP3A subfamily play a role in the metabolism of many anticancer drugs, including epipodophyllotoxins, ifosphamide, tamoxifen, taxol and vinca alkaloids. CYP3A4 has been shown to catalyse the activation of the prodrug ifosphamide, raising the possibility that ifosphamide could be activated in tumour tissues containing this enzyme. 3. As examples of recently found, clinically significant interactions, cyclosporin considerably increases plasma doxorubicin and etoposide concentrations. Although cyclosporin and calcium channel blockers may influence the pharmacokinetics of certain anticancer agents by inhibiting their CYP3A mediated metabolism, it is more likely that these P-glycoprotein inhibitors inhibit P-glycoprotein mediated drug elimination. 4. Appropriate caution should be exercised when combining P-glycoprotein inhibitors and potential CYP3A inhibitors with cancer chemotherapy.

Full text

PDF
524

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker D. K., Relling M. V., Pui C. H., Christensen M. L., Evans W. E., Rodman J. H. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol. 1992 Feb;10(2):311–315. doi: 10.1200/JCO.1992.10.2.311. [DOI] [PubMed] [Google Scholar]
  2. Balis F. M. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet. 1986 May-Jun;11(3):223–235. doi: 10.2165/00003088-198611030-00004. [DOI] [PubMed] [Google Scholar]
  3. Barbui T., Rambaldi A., Parenzan L., Zucchelli M., Perico N., Remuzzi G. Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet. 1992 Jun 6;339(8806):1421–1421. doi: 10.1016/0140-6736(92)91246-5. [DOI] [PubMed] [Google Scholar]
  4. Bartlett N. L., Lum B. L., Fisher G. A., Brophy N. A., Ehsan M. N., Halsey J., Sikic B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994 Apr;12(4):835–842. doi: 10.1200/JCO.1994.12.4.835. [DOI] [PubMed] [Google Scholar]
  5. Berg S. L., Cowan K. H., Balis F. M., Fisherman J. S., Denicoff A. M., Hillig M., Poplack D. G., O'Shaughnessy J. A. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19;86(2):143–145. doi: 10.1093/jnci/86.2.143. [DOI] [PubMed] [Google Scholar]
  6. Bickett D. J., MacKenzie P. I., Veronese M. E., Miners J. O. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci. 1993 Aug;14(8):292–294. doi: 10.1016/0165-6147(93)90043-j. [DOI] [PubMed] [Google Scholar]
  7. Botsch S., Gautier J. C., Beaune P., Eichelbaum M., Kroemer H. K. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120–126. [PubMed] [Google Scholar]
  8. Brockmöller J., Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet. 1994 Sep;27(3):216–248. doi: 10.2165/00003088-199427030-00005. [DOI] [PubMed] [Google Scholar]
  9. Buckley M. M., Goa K. L. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 1989 Apr;37(4):451–490. doi: 10.2165/00003495-198937040-00004. [DOI] [PubMed] [Google Scholar]
  10. Chang T. K., Weber G. F., Crespi C. L., Waxman D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993 Dec 1;53(23):5629–5637. [PubMed] [Google Scholar]
  11. Chen L., Waxman D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995 Feb 1;55(3):581–589. [PubMed] [Google Scholar]
  12. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J. M., Vieira I., Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994 Jan 15;54(2):386–392. [PubMed] [Google Scholar]
  13. Dechant K. L., Brogden R. N., Pilkington T., Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;42(3):428–467. doi: 10.2165/00003495-199142030-00006. [DOI] [PubMed] [Google Scholar]
  14. Erlichman C., Moore M., Thiessen J. J., Kerr I. G., Walker S., Goodman P., Bjarnason G., DeAngelis C., Bunting P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 1993 Oct 15;53(20):4837–4842. [PubMed] [Google Scholar]
  15. Evans W. E., Crom W. R., Abromowitch M., Dodge R., Look A. T., Bowman W. P., George S. L., Pui C. H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986 Feb 20;314(8):471–477. doi: 10.1056/NEJM198602203140803. [DOI] [PubMed] [Google Scholar]
  16. Evans W. E., Relling M. V. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet. 1989 Jun;16(6):327–336. doi: 10.2165/00003088-198916060-00001. [DOI] [PubMed] [Google Scholar]
  17. Fedeli L., Colozza M., Boschetti E., Sabalich I., Aristei C., Guerciolini R., Del Favero A., Rossetti R., Tonato M., Rambotti P. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer. 1989 Nov 1;64(9):1805–1811. doi: 10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. Fritz P., Behrle E., Beaune P., Eichelbaum M., Kroemer H. K. Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry. 1993 Jun;99(6):443–451. doi: 10.1007/BF00274096. [DOI] [PubMed] [Google Scholar]
  19. Gigante M., Toffoli G., Boiocchi M. Pharmacokinetics of doxorubicin co-administered with high-dose verapamil. Br J Cancer. 1995 Jan;71(1):134–136. doi: 10.1038/bjc.1995.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gonzalez F. J. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992 Sep;13(9):346–352. doi: 10.1016/0165-6147(92)90107-h. [DOI] [PubMed] [Google Scholar]
  21. Goren M. P., Wright R. K., Pratt C. B., Pell F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet. 1986 Nov 22;2(8517):1219–1220. doi: 10.1016/s0140-6736(86)92227-0. [DOI] [PubMed] [Google Scholar]
  22. Grochow L. B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993 Aug;20(4 Suppl 4):18–26. [PubMed] [Google Scholar]
  23. Grochow L. B., Jones R. J., Brundrett R. B., Braine H. G., Chen T. L., Saral R., Santos G. W., Colvin O. M. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55–61. doi: 10.1007/BF00694339. [DOI] [PubMed] [Google Scholar]
  24. Guengerich F. P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 1988 Jun 1;48(11):2946–2954. [PubMed] [Google Scholar]
  25. Harris J. W., Katki A., Anderson L. W., Chmurny G. N., Paukstelis J. V., Collins J. M. Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol. J Med Chem. 1994 Mar 4;37(5):706–709. doi: 10.1021/jm00031a022. [DOI] [PubMed] [Google Scholar]
  26. Harris J. W., Rahman A., Kim B. R., Guengerich F. P., Collins J. M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994 Aug 1;54(15):4026–4035. [PubMed] [Google Scholar]
  27. Henriksson R., Grankvist K. Interactions between anticancer drugs and other clinically used pharmaceuticals. A review. Acta Oncol. 1989;28(4):451–462. doi: 10.3109/02841868909092250. [DOI] [PubMed] [Google Scholar]
  28. Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol. 1991 Jun 15;41(12):1911–1919. doi: 10.1016/0006-2952(91)90131-n. [DOI] [PubMed] [Google Scholar]
  29. Jao J. Y., Jusko W. J., Cohen J. L. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 1972 Dec;32(12):2761–2764. [PubMed] [Google Scholar]
  30. Kerr D. J., Graham J., Cummings J., Morrison J. G., Thompson G. G., Brodie M. J., Kaye S. B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol. 1986;18(3):239–242. doi: 10.1007/BF00273394. [DOI] [PubMed] [Google Scholar]
  31. Kivistö K. T., Fritz P., Linder A., Friedel G., Beaune P., Kroemer H. K. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol. 1995 Jan;103(1):25–29. doi: 10.1007/BF01464472. [DOI] [PubMed] [Google Scholar]
  32. Kivistö K. T., Neuvonen P. J., Klotz U. Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet. 1994 Jul;27(1):1–5. doi: 10.2165/00003088-199427010-00001. [DOI] [PubMed] [Google Scholar]
  33. Kolars J. C., Lown K. S., Schmiedlin-Ren P., Ghosh M., Fang C., Wrighton S. A., Merion R. M., Watkins P. B. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994 Oct;4(5):247–259. doi: 10.1097/00008571-199410000-00003. [DOI] [PubMed] [Google Scholar]
  34. Kroemer H. K., Gautier J. C., Beaune P., Henderson C., Wolf C. R., Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332–337. doi: 10.1007/BF00169164. [DOI] [PubMed] [Google Scholar]
  35. Kumar G. N., Walle U. K., Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther. 1994 Mar;268(3):1160–1165. [PubMed] [Google Scholar]
  36. Le Guellec C., Lacarelle B., Catalin J., Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491–495. doi: 10.1007/BF00685896. [DOI] [PubMed] [Google Scholar]
  37. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  38. Lien E. A., Anker G., Lønning P. E., Solheim E., Ueland P. M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990 Sep 15;50(18):5851–5857. [PubMed] [Google Scholar]
  39. Liliemark J., Peterson C. Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet. 1991 Sep;21(3):213–231. doi: 10.2165/00003088-199121030-00005. [DOI] [PubMed] [Google Scholar]
  40. Loadman P. M., Bibby M. C. Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet. 1994 Jun;26(6):486–500. doi: 10.2165/00003088-199426060-00006. [DOI] [PubMed] [Google Scholar]
  41. Lum B. L., Kaubisch S., Yahanda A. M., Adler K. M., Jew L., Ehsan M. N., Brophy N. A., Halsey J., Gosland M. P., Sikic B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992 Oct;10(10):1635–1642. doi: 10.1200/JCO.1992.10.10.1635. [DOI] [PubMed] [Google Scholar]
  42. Mani C., Gelboin H. V., Park S. S., Pearce R., Parkinson A., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos. 1993 Jul-Aug;21(4):645–656. [PubMed] [Google Scholar]
  43. McLemore T. L., Adelberg S., Liu M. C., McMahon N. A., Yu S. J., Hubbard W. C., Czerwinski M., Wood T. G., Storeng R., Lubet R. A. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990 Aug 15;82(16):1333–1339. doi: 10.1093/jnci/82.16.1333. [DOI] [PubMed] [Google Scholar]
  44. Mimura M., Baba T., Yamazaki H., Ohmori S., Inui Y., Gonzalez F. J., Guengerich F. P., Shimada T. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos. 1993 Nov-Dec;21(6):1048–1056. [PubMed] [Google Scholar]
  45. Moore M. J. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1991 Mar;20(3):194–208. doi: 10.2165/00003088-199120030-00002. [DOI] [PubMed] [Google Scholar]
  46. Moore M. J., Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet. 1987 Oct;13(4):205–227. doi: 10.2165/00003088-198713040-00001. [DOI] [PubMed] [Google Scholar]
  47. Mross K., Maessen P., van der Vijgh W. J., Gall H., Boven E., Pinedo H. M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 1988 Mar;6(3):517–526. doi: 10.1200/JCO.1988.6.3.517. [DOI] [PubMed] [Google Scholar]
  48. Murray G. I., Paterson P. J., Weaver R. J., Ewen S. W., Melvin W. T., Burke M. D. The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma. Cancer. 1993 Jan 1;71(1):36–43. doi: 10.1002/1097-0142(19930101)71:1<36::aid-cncr2820710107>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  49. Murray G. I., Weaver R. J., Paterson P. J., Ewen S. W., Melvin W. T., Burke M. D. Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol. 1993 Mar;169(3):347–353. doi: 10.1002/path.1711690312. [DOI] [PubMed] [Google Scholar]
  50. Murray M., Butler A. M., Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J Pharmacol Exp Ther. 1994 Aug;270(2):645–649. [PubMed] [Google Scholar]
  51. Olkkola K. T., Aranko K., Luurila H., Hiller A., Saarnivaara L., Himberg J. J., Neuvonen P. J. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993 Mar;53(3):298–305. doi: 10.1038/clpt.1993.25. [DOI] [PubMed] [Google Scholar]
  52. Olkkola K. T., Backman J. T., Neuvonen P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 May;55(5):481–485. doi: 10.1038/clpt.1994.60. [DOI] [PubMed] [Google Scholar]
  53. Peck C. C., Temple R., Collins J. M. Understanding consequences of concurrent therapies. JAMA. 1993 Mar 24;269(12):1550–1552. [PubMed] [Google Scholar]
  54. Philip P. A., Joel S., Monkman S. C., Dolega-Ossowski E., Tonkin K., Carmichael J., Idle J. R., Harris A. L. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer. 1992 Feb;65(2):267–270. doi: 10.1038/bjc.1992.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rahman A., Korzekwa K. R., Grogan J., Gonzalez F. J., Harris J. W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994 Nov 1;54(21):5543–5546. [PubMed] [Google Scholar]
  56. Ratain M. J., Vogelzang N. J., Sinkule J. A. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987 Jan;41(1):61–67. doi: 10.1038/clpt.1987.9. [DOI] [PubMed] [Google Scholar]
  57. Relling M. V., Evans R., Dass C., Desiderio D. M., Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther. 1992 May;261(2):491–496. [PubMed] [Google Scholar]
  58. Relling M. V., Evans W. E., Fonné-Pfister R., Meyer U. A. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res. 1989 Jan 1;49(1):68–71. [PubMed] [Google Scholar]
  59. Relling M. V., Nemec J., Schuetz E. G., Schuetz J. D., Gonzalez F. J., Korzekwa K. R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352–358. [PubMed] [Google Scholar]
  60. Rushing D. A., Raber S. R., Rodvold K. A., Piscitelli S. C., Plank G. S., Tewksbury D. A. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer. 1994 Aug 1;74(3):834–841. doi: 10.1002/1097-0142(19940801)74:3<834::aid-cncr2820740308>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  61. Shah R. R. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view. Xenobiotica. 1993 Nov;23(11):1159–1193. doi: 10.3109/00498259309059432. [DOI] [PubMed] [Google Scholar]
  62. Speth P. A., van Hoesel Q. G., Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988 Jul;15(1):15–31. doi: 10.2165/00003088-198815010-00002. [DOI] [PubMed] [Google Scholar]
  63. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 1994 Jun;26(6):439–456. doi: 10.2165/00003088-199426060-00003. [DOI] [PubMed] [Google Scholar]
  64. Wainer I. W., Ducharme J., Granvil C. P., Trudeau M., Leyland-Jones B. Ifosfamide stereoselective dichloroethylation and neurotoxicity. Lancet. 1994 Apr 16;343(8903):982–983. doi: 10.1016/s0140-6736(94)90109-0. [DOI] [PubMed] [Google Scholar]
  65. Walker D., Flinois J. P., Monkman S. C., Beloc C., Boddy A. V., Cholerton S., Daly A. K., Lind M. J., Pearson A. D., Beaune P. H. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol. 1994 Mar 29;47(7):1157–1163. doi: 10.1016/0006-2952(94)90387-5. [DOI] [PubMed] [Google Scholar]
  66. Wei M. X., Tamiya T., Chase M., Boviatsis E. J., Chang T. K., Kowall N. W., Hochberg F. H., Waxman D. J., Breakefield X. O., Chiocca E. A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther. 1994 Aug;5(8):969–978. doi: 10.1089/hum.1994.5.8-969. [DOI] [PubMed] [Google Scholar]
  67. Weinshilboum R. M. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica. 1992 Sep-Oct;22(9-10):1055–1071. doi: 10.3109/00498259209051860. [DOI] [PubMed] [Google Scholar]
  68. Zhou-Pan X. R., Sérée E., Zhou X. J., Placidi M., Maurel P., Barra Y., Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 1993 Nov 1;53(21):5121–5126. [PubMed] [Google Scholar]
  69. Zhou X. J., Zhou-Pan X. R., Gauthier T., Placidi M., Maurel P., Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853–861. doi: 10.1016/0006-2952(93)90169-w. [DOI] [PubMed] [Google Scholar]
  70. Zorsky P. E., Perkins J. B. Optimizing high-dose therapy using pharmacokinetic principles. Semin Oncol. 1993 Oct;20(5 Suppl 6):2–18. [PubMed] [Google Scholar]
  71. van Maanen J. M., de Vries J., Pappie D., van den Akker E., Lafleur V. M., Retèl J., van der Greef J., Pinedo H. M. Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res. 1987 Sep 1;47(17):4658–4662. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES